Founded in 2007 and headquartered in Taipei, Bora Pharmaceuticals operates a dual-engine model that integrates contract development and manufacturing (CDMO) with commercial pharmaceutical operations. Originally focusing on central nervous system therapies and generics in Taiwan, the company has expanded through acquisitions and investments in small and large molecule manufacturing sites across Taiwan, Canada, and the U.S. Bora is committed to high-quality, efficient production and has obtained regulatory certifications including USFDA, MHRA, EMA and PIC/S, distributing pharmaceuticals to over 100 countries.

Key Products and Services

CDMO services – Offering formulation development, clinical and commercial scale manufacturing for small and large molecules across multiple global sites.

Pharma sales – Marketing and distributing generic and specialty products, with a strong presence in niche and rare disease markets.

Consumer healthcare & OTC – Developing and delivering over-the-counter products globally.

Global manufacturing infrastructure – State-of-the-art facilities in Taiwan, Canada (Mississauga), and the U.S. (Minnesota, Maryland), compliant with multiple international standards.

Strategic acquisitions & biologics expansion – Investments in biologics (e.g., Eden Biologics, Tanvex) and key acquisitions like Upsher-Smith Laboratories to scale capabilities and enter new markets.

Bora Pharmaceuticals continues to drive its ambition to be among the world’s top CDMOs by investing in talent, infrastructure, and strategic growth. With a robust global footprint, regulatory-accredited facilities, and a people-first culture, the company is well-positioned to deliver high-quality pharmaceutical solutions and accelerate access to essential medicines worldwide